• Something wrong with this record ?

Ginkgo biloba extract EGb 761® versus pentoxifylline in chronic tinnitus: a randomized, double-blind clinical trial

K. Procházková, I. Šejna, J. Skutil, A. Hahn,

. 2018 ; 40 (5) : 1335-1341. [pub] 20180601

Language English Country Netherlands

Document type Comparative Study, Journal Article, Randomized Controlled Trial

E-resources Online Full text

NLK ProQuest Central from 2011-02-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-02-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2011-02-01 to 1 year ago
Health & Medicine (ProQuest) from 2011-02-01 to 1 year ago

Background Ginkgo biloba extract EGb 761® and pentoxifylline are frequently prescribed for the treatment of tinnitus. Objective To compare the treatment effects of Ginkgo biloba extract EGb 761R and pentoxifylline. Setting The study was performed at Department of Otorhinolaryngology of University Hospital Královské Vinohrady and 3rd Medical Faculty, Charles University in Prague. Method Patients with sub-chronic or chronic tinnitus were enrolled in double-blind trial and randomized to receive 120 mg EGb 761® or 600 mg pentoxifylline, each twice a day and in double-dummy fashion over a 12-week period. Main outcome measure changes in 11-Point Box Scales for tinnitus loudness and annoyance, the abridged Tinnitus Questionnaire (Mini-TQ), the Hospital Anxiety and Depression Scale (HADS), and the Sheehan Disability Scale (SDS). Results Full analysis set for efficacy analysis comprised 197 patients (EGb 761®, 99; pentoxifylline 98). For both treatment groups, significant improvements were observed in the Mini-TQ, the 11-Point Box Scales for tinnitus loudness and annoyance, the HADS anxiety score and the SDS. There was no relevant difference with regard to tinnitus-related outcomes between the two treatment groups. 20 adverse events were documented in EGb 761® group and 36 adverse events were reported for pentoxifylline group. No serious adverse event was reported during the study. Conclusion EGb 761® and pentoxifylline were similarly effective in reducing the loudness and annoyance of tinnitus as well as overall suffering of the patients. The incidence of adverse events was lower in the EGb 761® group.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012637
003      
CZ-PrNML
005      
20220203082356.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11096-018-0654-4 $2 doi
035    __
$a (PubMed)29855986
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Procházková, Klára $u Department of Otorhinolaryngology, University Hospital Kralovske Vinohrady, Šrobárova 50, 10034, Prague, Czech Republic. klara.prochazkova@gmail.com. Third Faculty of Medicine, Charles University, Prague, Czech Republic. klara.prochazkova@gmail.com.
245    10
$a Ginkgo biloba extract EGb 761® versus pentoxifylline in chronic tinnitus: a randomized, double-blind clinical trial / $c K. Procházková, I. Šejna, J. Skutil, A. Hahn,
520    9_
$a Background Ginkgo biloba extract EGb 761® and pentoxifylline are frequently prescribed for the treatment of tinnitus. Objective To compare the treatment effects of Ginkgo biloba extract EGb 761R and pentoxifylline. Setting The study was performed at Department of Otorhinolaryngology of University Hospital Královské Vinohrady and 3rd Medical Faculty, Charles University in Prague. Method Patients with sub-chronic or chronic tinnitus were enrolled in double-blind trial and randomized to receive 120 mg EGb 761® or 600 mg pentoxifylline, each twice a day and in double-dummy fashion over a 12-week period. Main outcome measure changes in 11-Point Box Scales for tinnitus loudness and annoyance, the abridged Tinnitus Questionnaire (Mini-TQ), the Hospital Anxiety and Depression Scale (HADS), and the Sheehan Disability Scale (SDS). Results Full analysis set for efficacy analysis comprised 197 patients (EGb 761®, 99; pentoxifylline 98). For both treatment groups, significant improvements were observed in the Mini-TQ, the 11-Point Box Scales for tinnitus loudness and annoyance, the HADS anxiety score and the SDS. There was no relevant difference with regard to tinnitus-related outcomes between the two treatment groups. 20 adverse events were documented in EGb 761® group and 36 adverse events were reported for pentoxifylline group. No serious adverse event was reported during the study. Conclusion EGb 761® and pentoxifylline were similarly effective in reducing the loudness and annoyance of tinnitus as well as overall suffering of the patients. The incidence of adverse events was lower in the EGb 761® group.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a chronická nemoc $7 D002908
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pentoxifylin $x škodlivé účinky $x terapeutické užití $7 D010431
650    _2
$a rostlinné extrakty $x škodlivé účinky $x terapeutické užití $7 D010936
650    _2
$a psychiatrické posuzovací škály $7 D011569
650    _2
$a tinnitus $x farmakoterapie $x patofyziologie $x psychologie $7 D014012
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vazodilatancia $x škodlivé účinky $x terapeutické užití $7 D014665
651    _2
$a Česká republika $7 D018153
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Šejna, Ivan $u Department of Otorhinolaryngology, University Hospital Kralovske Vinohrady, Šrobárova 50, 10034, Prague, Czech Republic. Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Skutil, Jan $u Department of Otorhinolaryngology, University Hospital Kralovske Vinohrady, Šrobárova 50, 10034, Prague, Czech Republic. Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Hahn, Aleš, $u Department of Otorhinolaryngology, University Hospital Kralovske Vinohrady, Šrobárova 50, 10034, Prague, Czech Republic. Third Faculty of Medicine, Charles University, Prague, Czech Republic. $d 1947-2020 $7 nlk19990073180
773    0_
$w MED00180241 $t International journal of clinical pharmacy $x 2210-7711 $g Roč. 40, č. 5 (2018), s. 1335-1341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29855986 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20220203082350 $b ABA008
999    __
$a ok $b bmc $g 1391947 $s 1050942
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 40 $c 5 $d 1335-1341 $e 20180601 $i 2210-7711 $m International journal of clinical pharmacy $n Int J Clin Pharm $x MED00180241
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...